Show
Sort by
-
- Journal Article
- A1
- open access
The International Association for the Study of Lung Cancer lung cancer staging project : overview of challenges and opportunities in revising the nodal classification of lung cancer
-
Phase 3 randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC (NCT01780675)
-
Why did the randomized trial of prophylactic cranial irradiation with or without hippocampus avoidance in SCLC not reveal a difference?
-
- Journal Article
- A1
- open access
Reaction on the interpretation of the hippocampus avoidance prophylactic cranial irradiation trial in SCLC (NCT01780675)
-
Definition of synchronous oligometastatic non–small cell lung cancer : a consensus report
-
Real-world neurocognitive function in lung cancer : initial results of the PRO-Long study.
-
Health-related quality of life in KEYNOTE-010 : a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC (vol 14, pg 793, 2019)
-
Health-related quality of life in KEYNOTE-010 : a phase II/III study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC
-
Breath analysis by gas chromatography-mass spectrometry can be used to screen for pleural mesothelioma
-
Tumor regression gradient predicts disease free survival
-
Radiotherapy quality assurance of concurrent chemoradiotherapy in PROCLAIM phase III trial
-
Pembrolizumab vs docetaxel for previously treated NSCLC (KEYNOTE-010) : archival vs new tumor samples for PD-L1 assessment
-
Pembrolizumab vs docetaxel for previously treated NSCLC (KEYNOTE-010) : archival vs new tumor samples for PD-L1 assessment
-
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM Classification for Lung Cancer
-
Stereotactic Body Radiotherapy for Lung Cancer How Much Does it Really Cost?
-
Breath analysis by ion mobility spectrometry allows discrimination of pleural mesothelioma patients from controls
-
- Journal Article
- A1
- open access
Supplementary prognostic variables for pleural mesothelioma : a report from the IASLC Staging Committee
-
Outcome and prognostic factors of bronchopulmonary neuroendocrine tumors (BNETS): a single institutional series
-
Surgery in mesothelioma: where do we go after MARS?
-
A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer
-
Is postoperative FEV1 (poFEV1) more accurately estimated by functional respiratory imaging (FRI) than by conventional methods?
-
Screening tools for a high risk population: can we screen for early mesothelioma?
-
Volatile organic compounds as diagnostic tool for malignant pleural mesothelioma
-
Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomics
-
Proton radiotherapy for locally-advanced non-small cell lung cancer, a cost-effective alternative to photon radiotherapy in Belgium?
-
Second opinion for thoracic cancer and its impact on diagnosis and treatment strategy: a single institutional series
-
Resistance training in patients with radically treated respiratory cancer: mature results of a multi-centre randomised phase 3 trial (REINFORCE)
-
Initial analysis of the International Association For the Study of Lung Cancer Mesothelioma database
-
Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma
-
Activating EGFR mutations in patients with non small cell lung cancer: prevalence and predictors in a caucasian series
-
Effect of radical treatment on exercise capacity and muscle force in patients with intrathoracic cancer
-
Feasibility of epidermal growth factor receptor mutation testing in cytology samples
-
Carcinoma in situ at the bronchial resection margin: a review
-
Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group
-
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma
-
Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study
-
The role of EBUS-TBNA for the assessment of hilar lymph nodes
-
The IASLC Lung Cancer Staging Project A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer
-
EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodes-an International Multi-Centre Experience
-
Glomerular filtration rate is a confounder for determination of serum soluble mesothelin
-
Validation of soluble mesothelin: design and preliminary results of a Belgian multicentric observational study
-
Soluble mesothelin as a tool for early detection of malignant mesothelioma in asbestos-exposed workers
-
Trimodality treatment of early stage Malignant Pleural Mesothelioma (MPM): a single institutional experience
-
The International Association for the Study of Lung Cancer Staging Project Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer
-
The IASLC Lung Cancer Staging Project Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
-
Endoscopic and Endobronchial Ultrasonography According to the Proposed Lymph Node Map Definition in the Seventh Edition of the Tumor, Node, Metastasis Classification for Lung Cancer
-
Dendritic cell-based immunotherapy for malignant pleural mesothelioma
-
Response to chemotherapy predicts longer survival in an individual patient meta-analysis of 1205 patients with mesothelioma
-
A pilot phase II clinical trial of the 20S proteasome inhibitor bortezomib in patients with relapsed malignant pleural mesothelioma
-
The IASLC Lung Cancer Staging Project Data Elements for the Prospective Project
-
Is clinical to pathological (c to p) stage migration another Will Rogers phenomenon? An analysis of the IASLC staging database
-
Toxicity of EORTC 08031: phase 11 feasibility trial of induction chemotherapy (ICT) followed by extrapleural pneumonectomy (EPP) and postoperative radiotherapy (PORT) for malignant pleural mesothelioma (MPM) cT3N1M0 or less
-
Association of TGFβ1 polymorphisms involved in radiation toxicity with TGFβ1 secretion in vitro
-
Soluble mesothelin as a monitoring tool in the management of malignant mesothelioma patients
-
Pemetrexed (P) and Cisplatin (C) as either Induction (IC) or Adjuvant (AC) Chemotherapy in stage IB-II Non-Small Cell Lung Cancer (NSCLC): A randomized phase 2 study (EORTC 08051)
-
Muscle force and mass in patients with respiratory cancer: effects of radical treatment
-
Quantitative Perfusion Scintigraphy (QPS) or the Anatomic Segment Method (ASM) for estimating Postoperative Pulmonary Function (PF) in patients treated for non-small cel lung cancer (NSCLC): a retrospective comparison
-
Epidermal growth factor receptor protein expression and gene amplification in Caucasian patients with malignant pleural mesothelioma (MPM)
-
To what degree do patients with advanced lung cancer want to be informed and involved in medical decision-making?: a multicentre study in 13 hospitals in Belgium
-
Malignant giant solitary fibrous tumor of the mediastinum
-
EUS-FNA of enlarged necrotic lymph nodes may cause infectious mediastinitis
-
The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition
-
Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma - Results of an International Expanded Access Program
-
The yield of endoscopic ultrasound in lung cancer staging: Does lymph node size matter?
-
Reply: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer
-
Evidence-based supportive management in lung cancer
-
Predicting risk of radiation-induced lung injury
-
Transoesophageal endoscopic ultrasound with fine needle aspiration (EUS-FNA) in lung cancer staging: does lymph node size matter?
-
Chemotherapy in malignant mesothelioma: What's up, doc?
-
Systemic therapy of bronchioloalveolar carcinoma: Results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma
-
A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer